The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO Sarcoma and Rare Cancers 2023 | Unmet needs and precision oncology advancements in metastatic GIST
Robin Jones, MBBS, MRCP, MD, The Royal Marsden Hospital, London, UK, discusses the need for continuous drug development and clinical evaluation of tyrosine-kinase inhibitors (TKI) in the context of metastatic gastrointestinal stromal tumors (GIST). As TKI resistance is a common occurence in patients with advanced GIST, Prof Jones highlights that drugs such as avapritinib have demonstrated impressive response rates in tumors that harbor the PDGFRαD842 mutation and are therefore resistant to TKIs such as Imatinib. This interview took place at the ESMO Sarcoma and Rare Cancers Congress 2023 in Lugano, Switzerland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
